Your browser doesn't support javascript.
loading
Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.
Camacho, Niedzica; Van Loo, Peter; Edwards, Sandra; Kay, Jonathan D; Matthews, Lucy; Haase, Kerstin; Clark, Jeremy; Dennis, Nening; Thomas, Sarah; Kremeyer, Barbara; Zamora, Jorge; Butler, Adam P; Gundem, Gunes; Merson, Sue; Luxton, Hayley; Hawkins, Steve; Ghori, Mohammed; Marsden, Luke; Lambert, Adam; Karaszi, Katalin; Pelvender, Gill; Massie, Charlie E; Kote-Jarai, Zsofia; Raine, Keiran; Jones, David; Howat, William J; Hazell, Steven; Livni, Naomi; Fisher, Cyril; Ogden, Christopher; Kumar, Pardeep; Thompson, Alan; Nicol, David; Mayer, Erik; Dudderidge, Tim; Yu, Yongwei; Zhang, Hongwei; Shah, Nimish C; Gnanapragasam, Vincent J; Isaacs, William; Visakorpi, Tapio; Hamdy, Freddie; Berney, Dan; Verrill, Clare; Warren, Anne Y; Wedge, David C; Lynch, Andrew G; Foster, Christopher S; Lu, Yong Jie; Bova, G Steven.
Affiliation
  • Camacho N; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, United Kingdom.
  • Van Loo P; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
  • Edwards S; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.
  • Kay JD; Cancer Genomics Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Matthews L; Department of Human Genetics, University of Leuven, Leuven, Belgium.
  • Haase K; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, United Kingdom.
  • Clark J; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, Cambridgeshire, United Kingdom.
  • Dennis N; Molecular Diagnostics and Therapeutics Group, University College London, London, United Kingdom.
  • Thomas S; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, United Kingdom.
  • Kremeyer B; Cancer Genomics Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Zamora J; Norwich Medical School, University of East Anglia, Norwich, Norfolk, United Kingdom.
  • Butler AP; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Gundem G; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Merson S; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Luxton H; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Hawkins S; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Ghori M; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Marsden L; Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
  • Lambert A; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, United Kingdom.
  • Karaszi K; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, Cambridgeshire, United Kingdom.
  • Pelvender G; Molecular Diagnostics and Therapeutics Group, University College London, London, United Kingdom.
  • Massie CE; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, Cambridgeshire, United Kingdom.
  • Kote-Jarai Z; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Raine K; Department of Physiology, University of Oxford, Oxford, Oxfordshire, United Kingdom.
  • Jones D; Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, Oxfordshire, United Kingdom.
  • Howat WJ; Department of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, Oxfordshire, United Kingdom.
  • Hazell S; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, Oxfordshire, United Kingdom.
  • Livni N; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, Oxfordshire, United Kingdom.
  • Fisher C; Uro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, Cambridgeshire, United Kingdom.
  • Ogden C; CRUK Cambridge Centre, Early Detection Programme, Urological Malignancies Programme, Hutchison-MRC Research Centre, Cambridge, Cambridgeshire, United Kingdom.
  • Kumar P; Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, United Kingdom.
  • Thompson A; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Nicol D; Cancer, Ageing and Somatic Mutation, Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, United Kingdom.
  • Mayer E; Histopathology and in situ hybridization Research Group, Cancer Research UK Cambridge Institute, Cambridge, Cambridgeshire, United Kingdom.
  • Dudderidge T; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Yu Y; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Zhang H; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Shah NC; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Gnanapragasam VJ; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Isaacs W; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Visakorpi T; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Hamdy F; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Berney D; Department of Epidemiology, Second Military Medical University, Shanghai, China.
  • Verrill C; Department of Epidemiology, Second Military Medical University, Shanghai, China.
  • Warren AY; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom.
  • Wedge DC; Academic Urology Group, Department of Surgery, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom.
  • Foster CS; School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
  • Lu YJ; Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere and Tampere University Hospital, Tampere, Finland.
  • Bova GS; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, Oxfordshire, United Kingdom.
PLoS Genet ; 13(9): e1007001, 2017 Sep.
Article in En | MEDLINE | ID: mdl-28945760
ABSTRACT
A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. 64 recurrent regions of loss and gain were detected, of which 28 were novel, including regions of loss with more than 15% frequency at Chr4p15.2-p15.1 (15.53%), Chr6q27 (16.50%) and Chr18q12.3 (17.48%). Comprehensive mutation screens of genes, lincRNA encoding sequences, control regions and conserved domains within SCNAs demonstrated that a two-hit genetic model was supported in only a minor proportion of recurrent SCNA losses examined (15/40). We found that recurrent breakpoints and regions of inversion often occur within Knudson model SCNAs, leading to the identification of ZNF292 as a target gene for the deletion at 6q14.3-q15 and NKX3.1 as a two-hit target at 8p21.3-p21.2. The importance of alterations of lincRNA sequences was illustrated by the identification of a novel mutational hotspot at the KCCAT42, FENDRR, CAT1886 and STCAT2 loci at the 16q23.1-q24.3 loss. Our data confirm that the burden of SCNAs is predictive of biochemical recurrence, define nine individual regions that are associated with relapse, and highlight the possible importance of ion channel and G-protein coupled-receptor (GPCR) pathways in cancer development. We concluded that a two-hit genetic model accounts for about one third of SCNA indicating that mechanisms, such haploinsufficiency and epigenetic inactivation, account for the remaining SCNA losses.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Sequence Analysis, DNA / DNA Copy Number Variations / RNA, Long Noncoding Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: PLoS Genet Journal subject: GENETICA Year: 2017 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Sequence Analysis, DNA / DNA Copy Number Variations / RNA, Long Noncoding Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: PLoS Genet Journal subject: GENETICA Year: 2017 Type: Article Affiliation country: United kingdom